EXTENDED ADJUVANT HORMONAL THERAPY IN EARLY BREAST CANCER

Which women with HR+, early-stage breast cancer benefit from extended endocrine therapy?Подробнее

02_03 Adjuvant endocrine therapy for early breast cancerПодробнее

What Is Femara Letrozole And What Is It Used ForПодробнее

Endocrine Therapies for Breast CancerПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

MA-17Подробнее

Optimizing adjuvant endocrine therapy for early Breast CancerПодробнее

CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancerПодробнее

What Is The Success Rate For Femara In Breast CancerПодробнее

How to advance adjuvant hormonal therapy for BREAST CANCER? Improvement over TamoxifenПодробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice GuidelinesПодробнее

Dr. VK Gadi: Guideline Updates for Extended Endocrine Therapy Decision-MakingПодробнее

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623Подробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Adjuvant Treatment for Early Stage Hormone Positive Breast Cancer: Role of Genomic SignaturesПодробнее

2022 West Oncology Conference | Breast Cancers | Early-StageПодробнее

Dr. Reshma Mahtani: Guideline Updates for Extended Endocrine Therapy Decision-MakingПодробнее

Updates in the Treatment of Early Stage Breast CancerПодробнее

2021 ASCO Direct San Francisco | Early Stage Breast Cancer Summary | Dr. Mark PegramПодробнее